Technical Analysis for DERM - Dermira, Inc.

Grade Last Price % Change Price Change
grade A 13.58 -3.89% -0.55
DERM closed up 12.05 percent on Tuesday, March 19, 2019, on 7.83 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical DERM trend table...

Date Alert Name Type % Chg
Mar 19 New 52 Week Closing High Bullish -3.89%
Mar 19 Jack-in-the-Box Bullish Bullish Swing Setup -3.89%
Mar 19 Pocket Pivot Bullish Swing Setup -3.89%
Mar 19 Volume Surge Other -3.89%
Mar 19 Wide Range Bar Range Expansion -3.89%
Mar 19 Parabolic Rise Strength -3.89%
Mar 19 Upper Bollinger Band Walk Strength -3.89%
Mar 19 Inside Day Range Contraction -3.89%
Mar 19 Wide Bands Range Expansion -3.89%
Mar 19 Above Upper BB Strength -3.89%

Older signals for DERM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biopharmaceutical Alpha Psoriasis Acne Immunosuppressants Dermatology Skin Cutaneous Conditions Hyperhidrosis Inflammatory Skin Diseases Treatment Of Inflammatory Skin Diseases
Is DERM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.91
52 Week Low 5.9997
Average Volume 1,937,538
200-Day Moving Average 9.6516
50-Day Moving Average 7.5868
20-Day Moving Average 8.5015
10-Day Moving Average 8.856
Average True Range 1.219
ADX 30.55
+DI 51.5388
-DI 11.1211
Chandelier Exit (Long, 3 ATRs ) 11.253
Chandelier Exit (Short, 3 ATRs ) 10.397
Upper Bollinger Band 12.0095
Lower Bollinger Band 4.9935
Percent B (%b) 1.3
BandWidth 82.526613
MACD Line 0.7939
MACD Signal Line 0.3211
MACD Histogram 0.4728
Fundamentals Value
Market Cap 590.13 Million
Num Shares 41.8 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -5.23
Price-to-Sales 43.67
Price-to-Book 2.90
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.99
Resistance 3 (R3) 17.64 16.01 17.34
Resistance 2 (R2) 16.01 15.03 16.18 17.13
Resistance 1 (R1) 15.07 14.42 15.54 15.42 16.91
Pivot Point 13.44 13.44 13.68 13.61 13.44
Support 1 (S1) 12.50 12.46 12.97 12.85 11.35
Support 2 (S2) 10.87 11.85 11.04 11.13
Support 3 (S3) 9.93 10.87 10.92
Support 4 (S4) 10.28